WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.074
Volume 8, Issue 10, 870-888. Research Article ISSN 2277– 7105

PREPARATION OF IN-VITRO EVALUATION OF PROLIPOSOME OF NITROFURANTOIN

Hemant Kumar* and Mallikarjuna B. P.

IIMT College, Pharmacy Institute, Knowledge Park-II Greater Noida, Uttar Pradesh 201301.

Article Received on
25 June 2019,

Revised on 15 July 2019,
Accepted on 04 August 2019,

DOI: 10.20959/wjpr201910-15541

***Corresponding Author**
Hemant Kumar
IIMT College, Pharmacy Institute, Knowledge Park-II Greater Noida, Uttar Pradesh 201301.

ABSTRACT

The objective of any medication conveyance framework is to give helpful measure of medication to the best possible site in the body and furthermore to accomplish and keep up the ideal plasma centralization of medication for a specific timeframe. In any case, inadequate arrival of medication, shorter residence time of dosage form in the gastrointestional tract and high hepatic first pass effect prompts lower bioavailability. Such confinements of the regular doses structures have cleared to a time of controlled and novel medication conveyance frameworks. Nitrofurantoin is exceedingly steady to the improvement of bacterial obstruction, a property thought to be because of its assortment of instruments of activity. Nitrofurantoin is actuated by bacterial flavoproteins (nitrofuran reductase) to dynamic decreased receptive intermediates that are thought to adjust and harm ribosomal proteins or different macromolecules, particularly DNA, causing hindrance of DNA, RNA, protein, and cell divider union. The general impact is restraint of bacterial development or cell demise. Nitrofurantoin is suffering from some limitation such as poor bioavailability, low solubility and very less half life. Before proliposomes development, preformulation studies were carried out to describe the compound and physical properties of medication substance. The FT-IR range of drug samples was found to be in concordant with the reference chemical groups present in the structure of the Nitrofurantoin. The standard curves of Nitrofurantoin were prepared DMF and the absorbance information acquired exposed to direct relapse. The connection coefficients were observed for Nitrofurantoin which is closed to one indicated for good linearity. The preformulation consider (FT-IR range, UV range and liquefying point) results recommended that Nitrofurantoin was unadulterated and great in quality and the estimation strategy was observed to be very dependable, precise and appropriate for definition improvement.

KEYWORDS: Nitofurantoin, preformulation, prelisosomes.

1. INTRODUCTION

The Liposome is gotten from Greek words: "Lipos" which means fat and "Soma" which means body.[1] Out of all the novel medication conveyance frameworks, liposomes are viewed as the best, explored and comprehensively.[2] A small scale circular vesicle comprising of a watery center encased in phospholipid particles is known as liposome. Medication atoms can be consolidated into the fluid stage or inside the lipid bilayer. They are generally utilized as a vehicle for organization of supplements and pharmaceutical medications to improve the security and viability of medication by diminishing the reactions.[3] To enter the market, Liposomes should stay steady and flawless during the capacity time frame and before achieving the focused on location to create restorative activity. Notwithstanding, because of physical and compound flimsiness, liposomes are generally flimsy colloidal frameworks.[4] Liposomal suspension may have constrained timeframe of realistic usability and to defeat the soundness issue related with liposome, another "star liposome" strategy is built up that can deliver liposomes immediately when there is a need and without over the top control.[5] Professional liposomes (Proliposomes) were found in 1986.[6] Expert liposomes are without dry streaming granular items that on hydration or on contact with organic liquids in the body, structure liposomal scattering. They are made out of water dissolvable permeable powder and phospholipid.[7] For delivering business liposome items, Pro-liposome is a standout amongst the most broadly utilized and financially savvy techniques. As they are accessible in dry powder structure, it's anything but difficult to disperse, move, measure and store, making it an assorted framework. Liposomes can either be framed in vivo by the impact of natural liquids in the body or in vitro utilizing an appropriate hydrating liquid before the organization.[8] Dissolvability and bioavailability issues of numerous medications can be overwhelmed by growing expert liposomal plans.

2. MATERIALS AND METHOD

Preformulation studies are the leading phase in the improvement of measurement shapes that can be well-defined as “investigation of physical and chemical properties of a drug substance alone and when it combines with excipients”.[10] These physicochemical studies should concentrate on properties of another compound that could influence the medication development and performance of an effective measurement structure. A careful

comprehension of physicochemical properties of a drug is necessary that may at last give a basis definition structure or bolster the requirement for atomic adjustment.[9]

The goals of preformulation are

- To establish the necessary physiochemical parameters of new drug substances.
- To determine kinetic rate profile.
- To establish physical characteristics.
- To establish compatibility with common excipient.

Therefore, preformulation studies are compulsory to set up the identity and physicochemical parameter[11] of selected drug combination Nitrofurantoin was subjected for following investigations.

- Organoleptic Properties
- UV- VIS spectroscopy
- FTIR spectroscopy
- Melting point
- Partition coefficient
- Solubility

3-PERFORMULATION STUDIES

The aim of preformulation studies is to investigate the physical and chemical properties of a drug substance. The selected drug Nitrofurantoin was subjected for investigation of physical characterization parameters such as.

- Organoleptic properties
- UV-visible spectra
- FT-IR spectra
- Melting point
- Solubility
- Partition coefficient

3.1. Organoleptic Properties

Organoleptic properties of drug Nitrofurantoin found to be as per I.P. monograph. The Organoleptic properties of Nitrofurantoin were found to the given.

Table 1: Organoleptic Properties of Nitrofurantoin.

Sr. no.	Properties	Inferences
1.	Colour	Yellowish
2.	Odour	Odourless
3.	Form	Crystalline
4.	Taste	Bitter

3.2. UV Spectroscopy

3.2.1. UV-visible spectroscopy

UV absorption maxima (λ_{max}) of Nitrofurantoinin DMF was determined by using UV-visible spectrophotometer and shown in **Figure 1 and Table 2.** Drug exhibited maxima at 376 nm.



Figure 1: UV-visible spectrum of Nitrofurantoinin DMF.

Table 2: Absorption maxima (λ_{max}) of Nitrofurantoin.

Observed absorption maxima	Reported absorption maxima
376 nm	376 nm

7.1. Preparation of standard curve of Nitrofurantoinin DMF

Table 2: Calibration curve of Nitrofurantoinin DMF (λ_{max} = 376 nm).

S.No	Concentration (µg/ml)	Absorbance (mean ±SD)
1	1	0.097 ±0.001
2	2	0.162 ±0.003
3	3	0.247 ±0.001
4	4	0.323 ±0.002
5	5	0.399 ±0.003
6	6	0.479 ±0.004
7	7	0.561 ±0.006
8	8	0.628 ±0.001
9	9	0.714 ±0.003
10	10	0.812 ±0.0026

All values are expressed as mean ± SD; n = 3



Figure 2: Graph of standard calibration curve of Nitrofurantoin in DMF.

Table 3: Result of regression analysis of UV method for estimation of Nitrofurantoin.

Statistical parameters	Results
λ max	376 nm
Regression equation ** Y=mx+C	Y=0.078x-0.009
Slope (b)	0.078
Intercept (C)	0.009
Correlation coefficient (r^2)	0.999

The calibration curve for Nitrofurantoin was obtained by using the 1 to 10 µg/ml solution of Nitrofurantoin in DMF. The absorbance was measured at 376 nm. The calibration curve of Nitrofurantoin as shows in graph indicated the regression equation Y=0.078x-0.009 and R^2 value 0.999, which shows good linearity.

7.1.3. Melting point determination

The liquefying purpose of a substance is the temperature at which the strong stage gets converted to fluid stage under the one climate of weight.[12] The liquefying point determination implies the purity of drug. Softening purpose of Nitrofurantoin was dictated by narrow cylinder technique and was found to be quite similar to the reported melting point as shown.

Table 4: Melting point of Nitrofurantoin.

Drug	Reference M.P.	Observed M.P.
Nitrofurantoin	261-263°C	265-269°C

Value is expressed as mean ± SD; n = 3

Discussion: The melting point of Nitrofurantoin was found to be in range 265-269°C which is of the pure drug. Hence drug sample was free from any type of impurities.

7.1.4. Partition coefficient determination

Segment coefficient of the Nitrofurantoin was resolvedusing n-octanol & water. Log P more prominent than one demonstrates that the medication is lipophilic in nature, while those with segment coefficients short of what one are characteristic of a hydrophilic medication.[13] This showed the lipophilicity and immaculateness of medication.

Table 5: Partition coefficient determination of Nitrofurantoin.

Partition coefficient of drug	Solvent system	Log p Values
Nitrofurantoin	n-octanol:water	1.39± 0.07

Value is communicated as mean± SD; n = 3

Discussion: The partition coefficient of Nitrofurantoin in n- Octanol: Water was found to be 1.39 this indicates that the drug is lipophillic in nature.

7.1.5. FT-IR spectral analysis

FT-IR investigation estimates the specific assimilation of light by the vibration methods of explicit substance bonds in the sample. The FT-IR spectrum of Nitrofurantoin is shown in and interpretation of data is given.



Figure 3: FTIR Spectrum of Nitrofurantoin Drug.

Table 6: FT-IR interpretation data of Nitrofurantoin.

Observed peak (cm^{-1})	Functional group
2367.98	HC=N bond
3276.75	N-H stretching
1725.79	C=O group
1516.12	N-O Asymmetric stretching
1107.84	C-O-C group
2855.57	C-H bond

The main infrared peaks of the Nitrofurantoin are as follows: The FTIR spectra of Nitrofurantoinpure are given. The prominent peaks for various groups are N–H stretching at 3276.75 cm^{-1}, HC=N bond at 2367.98 cm^{-1}, C=O group at 1725.79 cm^{-1}, N-O asymmetric stretching at 1516.12 cm^{-1}, C-O-C group at 1107.84 cm^{-1} and C–H bond at 2855.57 cm^{-1}. The observed FT-IR spectrum confirmed and identified the presence of functional groups and purity of the drug.

7.1.6. Drug-excipients compatibility study by FTIR



Figure 4: FTIR spectrum of physical mixture (Pure Nitrofurantoin + excipients).

The FTIR spectra of pure Nitrofurantoin showed characteristic peaks 2367.98 cm^{-1} at HC=N bond, 3276.75 cm^{-1} at N-H stretching, 1725.79 cm^{-1} at C=O group, 1516.12 cm^{-1} at N-O asymmetric stretching, 1107.84 cm^{-1} at C-O-C group, 2855.57 cm^{-1} C-H bond respectively. From the physical blends of medication and excipients there were no significant moving just as no loss of any useful crests between the spectra of medication and its physical blends Hence, it was confirmed that there w78.17 as no connection between the medication and excipients utilized.

7.1.7. Solubility studies

Dissolvability of medication in different solvents, were done so as to screen for the parts to be utilized for detailing advancement. Examination of the medication was done on UV Spectrophotometer at376 nm.

Table 7: Solubility studies of Nitrofurantoin for different solvents.

Sr.no	Solvent	Solubility in (mg/ml) (mean±SD) *
1	Acetone	5.780±0.002
2	Chloroform	0.218±0.0015
3	Ethanol	0.568±0.009
4	Methanol	0.391±0.004
5	6.8 phosphate buffer	0.113±0.004
6	0.1NHCl	0.094±0.002
7	Water	0.220±0.002
8	7.4phosphate buffer	0.136±0.002
9	DMSO	30.27±0.003
10	DMF	43.26±0.002

* Each value is average of three independent determinations



Figure 5: Solubility study of drug in different solvents.

Discussion: Nitrofurantoin highly soluble in DMF (43.26 mg/ml) and DMSO (30.27 mg/ml) and drug is less soluble in rest of solvents.

7.2. Characterization of Proliposomes

7.2.1. Microscopy of Proliposomes

The prepared proliposomes delivery systems were made of lecithin, cholesterol, mannitol which is biologically inert, non-irritating, nonmutagenic, non-allergenic, non-toxic and biodegradable. As a result, the human body cannot convert them into other substances or break them down.

Table 8: Appearance of different Proliposomes formulation under light Microscope.

S.no.	Formulation code	Appearance
1	F1	Proliposomes was not formed
2	F2	Proliposomes was not formed
3	F3	Proliposomes was not formed
4	F4	Irregular shape Proliposomes was formed
5	F5	Irregular shape Proliposomes was formed
6	F6	Irregular shape Proliposomes was formed
7	F7	Spherical shape Proliposomes was formed
8	F8	Spherical shape Proliposomes was formed
9	F9	Spherical shape Proliposomes was formed
10	F10	Irregular Spherical Proliposomes was formed
11	F11	Spherical shape Proliposomes was formed
12	F12	Spherical shape Proliposomes was formed
13	F13	Spherical shape Proliposomes was formed
14	F14	Irregular shape Proliposomes was formed
15	F15	Irregular shape Proliposomes was formed



Figure 5: Microscopical of Nitrofurantoin loaded Proliposomes.

it was found that F7, F8, F9 and F11,F12, F13 formulations were spherical in shape but F4, F5, F6, F10, F14, F15 found to be irregular shape due to aggregation of particles. For the most part, little liposomal vesicles will in general total to frame enormous vesicles however cholesterol decline the conglomeration upto a limit, consequently increment the number of

inhabitants in stable little liposome vesicles. Mannitol gives base to phospholipid to store. Lessening in vesicle measure with increment in mannitol fixation could be credited to increment in accessible surface territory for phospholipid to store.[13] As the centralization of mannitol was diminished, a sticky item with poor flowability was acquired because of expanded phospholipid load as for mannitol. On the basis shape formulation all formulation was selected for further evaluation.

7.2.2 Percentage yield

Percentage yield of proliposomes were given.

Table 9: Percentage yield of Proliposomes formulations.

S.no.	Formulation Code	Percentage Yield
1	F1	80.35±0.99
2	F2	91.57±0.49
3	F3	86.08±1.02
4	F4	80.76±1.62
5	F5	91.59±2.11
6	F6	81.91±1.91
7	F7	85.46±0.55
8	F8	88.06±0.52
9	F9	86.46±0.81
10	F10	85.14±1.32
11	F11	92.59±0.96
12	F12	90.28±0.48
13	F13	89.48±0.81
14	F14	91.10±0.79
15	F15	90.19±0.57



Figure 6: Percentage yield of different Proliposomes formulations.

Discussion: Maximum percentage yield of all formulation was found to be in a range of found in range of 80.35±0.99 & 92.59±0.96.

7.2.3. Percentage drug entrapment

Percentage yield and drug entrapment of Proliposomes were given.

Table 10: Percentage drug entrapment of Proliposomes formulations.

S.No.	Formulation Code	Percentage drug entrapment
1	F1	29.48±0.177
2	F2	41.7±0.65
3	F3	39.18±0.627
4	F4	59.49±0.243
5	F5	63.19±0.442
6	F6	63.01±0.539
7	F7	70.92±0.152
8	F8	77.48±0.537
9	F9	74.71±0.529
10	F10	74.71±0.204
11	F11	58.39±0.165
12	F12	62.28±022
13	F13	57.96±0.241
14	F14	52.36±0.565
15	F15	61.91±0.513



Figure 7: Percentage drug entrapment of different Proliposomes formulations.

Discussion: The entrapment efficiency of proliposomes formulations is shown**.** Entrapment efficiency range varied from 29.48±0.177% to 77.48±0.537% for different combinations of factors. The result proposed that factors; Phospholipid and Cholesterol fixation critical impact

on EE% of shaped proliposomes. There was increment in EE% with increment in phospholipid and abatement in EE% with increment in cholesterol fixation upto a limit quantity. Medication which gets entangled in phospholipid bilayer. Therefore, increment in phospholipid focus prompts increment in capture effectiveness of medication. Increment in cholesterol fixation decline the EE%. At low centralization of cholesterol, sharp increment in EE% was seen with increment in phospholipid while at high convergence of cholesterol, with increment in phospholipid minor increment in EE% was watched. Formulation F8 was the optimized formulation among all nitrofurantoin loaded proliposomes formulations. F8 showed good entrapment of drug and compatibility with lipid.

5.2.4. Vesicle size analysis



Figure 8: Vesicle size analysis.

The result indicates obtained proliposome population have narrow size distribution vesicle size was found to be 427.8 nm of optimized formulation (F8) as shown in **Figure 17**.

5.2.5. FTIR spectral analysis



Figure 9: FTIR of formulation (F8).

Infrared investigations were done to affirm the similarity between the lipid, sedate, and chose proliposomes definition. From the spectra it was seen that there was no real moving, just as, no loss of utilitarian crests between the spectra of the medication, lipid, and medication stacked Proliposomes.

As seen from the broad absorption band C–O extending vibration in ester gathering appears at 1173 cm^{-1}. Theretention tops at 2924 cm-1 is attributed to the extending vibration of $–CH_3$. The bending vibration of $–CH_3$ occurs at 1458 cm^{-1}. The trademark ingestion top at 1173 cm-1 is gotten from the C–O–C extending vibration.

Discussion: The absence and low peak intensity of drug shows entrapment of drug in developed Proliposomes.

5.2.6 Analysis of TEM

5.3. *In vitro* drug release study of Proliposomes

The discharge profiles of F8 were studied w.r.t. to pure nitrofurantoin as control. Plans showed a biphasic supported discharge design and an underlying burst discharge viz. 11.3% and 28% of nitrofurantoin was obtained from F8, respectively in the PBS[14] conceivable reason that might be accounted is the quick arrival of medication adsorbed on the outside of the Proliposomes or captured in the peripheral stratum. Further, the % medication discharge frompure nitrofurantoinwas 100% at the end of 2h. But nitrofurantoin loaded Proliposomes

(F8) followed continued and delayed discharge mien of medication particles watched was for the most part because of dispersion of medication through the lipoidal lattice of the Proliposomes. As obvious from the inset chart, fundamentally higher arrival of pure nitrofurantoin as compared to that of F8was This may perhaps be because of auxiliary trustworthiness presented by lipid subsequently giving a lipid barrier to diffusion of drug.

Table 11: *In vitro* drug release profile of pure drug, formulation F8.

Time (h)	% Drug release	
	Pure Drug	F8
0.08	8.03±001	2.3±0.05
0.25	19.79±0.35	5.59±0.06
0.5	36.57±0.26	10.43±0.04
0.75	64.71±0.23	19.54±0.18
1	80.26±0.35	27.72±0.07
2	100.67±0.4	37.73±0.58
3		44.53±0.69
4		49.32±0.58
5		54.2±0.26
6		57.83±0.13
7		60.83±0.81
8		63.09±0.48



Figure 10: *In vitro* drug release profile of pure drug, formulation F8.

5.3.1. Drug release kinetics

In-vitro drug release kinetic study data of formulation F8 was given below.

Zero order

Zero order graph % drug release vs. Time.



Figure 11: Zero order kinetics of F8 formulation.

First order

First order graph Log % drug remaining vs. time



Figure 22: First order kinetics of F8 formulation.

Higuchi kinetics

Higuchi release kinetics log %drug release vs. Square root of time.



Figure 12: Higuchi kinetics of F8 formulation.

Korsmeyer peppas

Korsmeyer peppas release kinetics Log % drug release vs Log time



Figure 13: Korsmeyer peppas Model of F8 formulation.

Table 12: Kinetic equation parameter of F8 formulation.

Formulation Name	Zero order		First order		Higuchi		Korsymer-peppas	
	R^2	K_0	R^2	K_0	R^2	K_0	R^2	K_0
F8	0.880	7.427	0.946	-0.055	**0.972**	24.92	0.957	1.336

Numerical models are usually used to anticipate the discharge component and look at discharge profile. For all the optimized definitions, the % medication discharge versus time

(zero request), log percent medication remaining versus time (first request), log percent medication discharge versus square base of time (Higuchi plot), and log of log % medication discharge versus log time (Korsmeyer and Peppas Exponential Equation) were plotted.[15] For each situation, R2 worth was determined from the chart and detailed in**.** Thinking about the assurance coefficients, Higuchi model was found to fit the discharge information best. This exhibits nitrofurantoin particles were scattered in the Proliosomes and there was no connection between the medication and plan material. It could be concluded from the results that the medication was discharged from Proliposomes by a dispersion controlled instrument.

RESULTS AND DISCUSSION

Lipid-based frameworks are known to improve the bioavailability of hydrophobic bioactives, which make these lattices particularly fascinating as exemplification frameworks. Late advances have appeared one of the ways to deal with improve the half life and bioavailability substances, for example, Nitrofurantoin is to fuse these mixes in lipid-based exemplification frameworks.

Before proliposomes development, preformulation studies were carried out to describe the compound and physical properties of medication substance. The FT-IR range of drug samples was found to be in concordant with the reference chemical groups present in the structure of the Nitrofurantoin. The UV spectrum of Econazole nitrate in DMF exhibited a broad band at 376 nm. The liquefying point was dictated by fine strategy which complies with the melting point given in pharmacopoeia. The solubility results showed that Nitrofurantoin is soluble in DMF and dimethylsulfoxide, practically insoluble in water. The dissolvability profile of medication in various solvents shows that drug is lipophilic in nature which is further confirmed by the partition coefficient study.

The preformulation consider (FT-IR range, UV range and liquefying point) results recommended that Nitrofurantoin was unadulterated and great in quality and the estimation strategy was observed to be very dependable, precise and appropriate for definition improvement.

Proliposomes formulation of Nitrofurantoin was prepared by using thin film technique.

For optimization of Proliposomes, different formulations (F1 to F15) were prepared using the various quantities of lipid and cholesterol. Formulation (F8) with maximum entrapment efficiency and optimum size considered as optimized formulation.

The shape and size of the optimized F8 formulation was confirmed through microscope and TEM study and found that most of the particles were well identified, spherical and discreet having large internal aqueous space.

Optimized formulations were incorporated in to capsules and *in vitro* drug release was studied in aqueous media using USP 1 dissolution apparatus. To know precisely, the rate and mechanism of drug release, the *in vitro* data was fitted to zero order, first order, Higuchi and Korsmeyer-Peppas model. The results showed that the drug release from all formulations followed Higuchi order which describes that the Nitrofurantoinfollows a diffusion mechanism for release from Proliposomes.

REFERENCES

1. Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and applications. Int J Pharm Stud Res, 2012; 3: 14-20.
2. Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J pharm, 2009; 380: 96-104.
3. Sun C, Wang J, Liu J, Qiu L, Zhang W, et al. Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. Aaps Phar, 2013; 14: 332-338.
4. Yadav A, Murthy MS, Shete AS, Sakhare S. Stability aspects of liposomes. Ind J Pha Edu, 2011; 45: 402-413.
5. Uchegbu LF. Publisher: CRC Press, 2000; 93-96.
6. Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. Proliposomes: a novel solution to an old problem. J pha sc, 1986; 75: 325-329.
7. Manjula D, Shabaraya AR, Shyale S. Topical Delivery of Fenoprofen Proliposomes: Preparation, Evaluation and In Vitro Release. Int J Pha Sc In, 2014; 3: 06-12.
8. Janga KY, Jukanti R, Velpula A, Sunkavalli S, Bandari S, et al. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. Eur J Phar Bio, 2012; 80: 347-357.
9. S Bansal; CP Kashyap; G Aggarwal; SL Harikumar. A comparative review on vesicular drug delivery system and stability issues. IJRPC, 2012; 2(3): 04-713.
10. Lasic DD, Papahadjopoulos D, Liposomes and biopolymer in drug and gene deliver, Current Opinion in Solid State and Materials Science, 1996; 1: 392-400.

11. Sanjay K Jain and Jain N K. Liposomes as Drug Carriers. Controlled and novel drug delivery, CBS publishers and distributors, Delhi, 2008; 304-342.
12. Gupta V, Barupal A K, Ramteke S. Formulation development and in vitro characterization of proliposomes for topical delivery of Aceclofenac, Indian J Pharm Sci, 2008; 70: 768-75.
13. Janga K Y, Jukanti R, Velpula A. Bioavailability enhancement of Zaleplonvia proliposomes: Role of surface charge, Euro J Pharm and Biopharm, 2012; 80(2): 347-357.
14. Song KH, Chung SJ, Shim CK. Preparation and evaluation of proliposomes containing salmon calcitonin. J Con Rel, 2002; 84: 27-37.
15. Janga KY, Jukanti R, Velpula A, Sunkavalli S, Bandari S, et al. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. Euro J Phar Biop, 2012; 80: 347-357.